By Don Nico Forbes
Atara Biotherapeutics said the U.S. Food and Drug Administration placed a clinical hold on its active investigational new drug applications.
The biotechnology company said the FDA put a hold on its Ebvallo and ATA3219 programs due to compliance issues at a third-party manufacturing facility. Ebvallo is a treatment candidate for Epstein-Barr virus positive post-transplant lymphoproliferative disease, or EBV+PTLD. ATA3219 is a candidate for the treatment of non-Hodgkin's lymphoma and systemic lupus erythematosus.
The company noted that the issues don't affect its Fujifilm Diosynth Biotechnologies third-party facility in Thousand Oaks, Calif.
Atara added that it has agreed with the FDA upon necessary actions to release the clinical holds.
"We intend to work closely with the FDA to address these issues as expeditiously as possible," said Chief Executive Cokey Nguyen.
Shares of Atara fell 4.3% to $6.29 in premarket trading Tuesday.
Write to Don Nico Forbes at don.forbes@wsj.com
(END) Dow Jones Newswires
January 21, 2025 08:14 ET (13:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。